RIT2

Across TCGA pan-cancer cohorts, RIT2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RIT2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher RIT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RIT2 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

THCA, LIHC, and SKCM are the cancer types where RIT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.061	0.828	<.001	18	view →
LIHC	DFS	Median	All	0.099	0.555	.002	18	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	17	view →
SARC	DFS	Median	All	0.069	0.632	<.001	9	view →
HNSC	OS	Median	II,III,IV	0.196	0.710	.023	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	1.000	0.365	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RIT2–THCA (DFS)

Open the THCA breakdown →